MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturity and sale of
available-for-sale securities
$295,871K
Proceeds from sale of
investment in arrowhead...
$174,095K
Net cash provided by
(used in) investing...
$69,641K
Canceled cashflow
$400,325K
(decrease) increase in cash
and cash...
-$304,182K
Canceled cashflow
$69,641K
Decrease (increase) in
accounts receivable
-$203,755K
Non-cash inventory
write-downs for excess and...
$165,257K
Stock-based compensation
$123,396K
Increase (decrease) in
accounts payable,...
$104,269K
Decrease (increase) in
manufacturing-related deposits and...
-$78,840K
Increase (decrease) in
deferred revenue
$72,051K
In-kind milestone
payment to arrowhead...
$50,000K
Depreciation and
amortization
$44,521K
Loss on investment in
arrowhead...
-$17,293K
Non-cash write-off of
prepaid deposits
$17,041K
Reduction in the carry
amounts of the right of...
$13,951K
Non-cash interest
expense
$13,532K
Other
-$7,055K
Proceeds from issuance of
common stock
$20,000K
Proceeds from exercise of
stock options and...
$18,703K
Acquisition of strategic
investments
-$245,819K
Purchase of property and
equipment
$101,972K
Purchase of
available-for-sale securities
$44,658K
Purchase of intangible
assets and other
$7,876K
Net cash used in
operating activities
-$205,479K
Net cash (used in)
provided by financing...
-$168,344K
Canceled cashflow
$910,961K
Canceled cashflow
$38,703K
Net (loss) income
-$713,410K
Repayment of 2027 notes,
including debt...
$158,418K
Repurchases of common stock,
net of excise tax
$25,013K
Increase in inventory
$301,093K
(increase) decrease in
other assets
$79,784K
(gain) loss on debt
extinguishment
$16,862K
Accretion of investment
discount, net
-$5,291K
Debt issuance costs
for the august 2025...
$17,060K
Payments related to
revolving credit facility
$4,170K
Common stock issuance
costs
$2,386K
Back
Back
Cash Flow
source: myfinsight.com
logo (1) copy-svg
Sarepta Therapeutics, Inc. (SRPT)
logo (1) copy-svg
Sarepta Therapeutics, Inc. (SRPT)